CORRESPONDENCE
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made. Table S1 ). The following variables were significantly associated with greater hemoglobin increases from baseline at 16 weeks: ferric citrate treatment (P < .0001), lower baseline hemoglobin (P 5 .0160), higher serum albumin (P 5 .0007), lower intact fibroblast growth factor 23 (FGF23; P 5 .0024), and lower TSAT (P 5 .0189) (Supporting Information Table   S2 ; Sensitivity Analyses). Treatment interactions were retained for TSAT and ferritin only.
The treatment effect of ferric citrate versus placebo on hemoglobin was greater among patients with lower baseline TSAT than those with higher baseline TSAT. The estimated LSM difference at 16 weeks was 1.16 g/dL (95% CI, 0.84-1.48; P < .0001) at TSAT 15% and 0.78 g/dL (95% CI, 0.48-1.08; P < .0001) at TSAT 24% (treatment 3 baseline TSAT 3 week 16 interaction P 5 .0426). Ferric citrate-treated patients with lower versus higher baseline TSAT showed a greater rate of hemoglobin rise ( Figure 1A) .
Similarly, the treatment effect of ferric citrate versus placebo was greater among patients with lower baseline ferritin (estimated LSM difference at ferritin 35 ng/mL, 1.12 g/dL; 95% CI, 0.78-1.45; P < .0001) than patients with higher baseline ferritin (estimated LSM difference at ferritin 126 ng/mL, 0.79 g/dL; 95% CI, 0.46-1.12; P < .0001; treatment 3 baseline ferritin 3 week 16 interaction, P 5 .0974). Ferric citrate-treated patients with lower versus higher baseline ferritin showed a greater rate of hemoglobin rise ( Figure 1B ). PBO), BL albumin, BL log iFGF23, BL TSAT, week, treatment 3 week interaction, treatment 3 TSAT interaction, and treatment 3 week 3 TSAT interaction as fixed effects, and BL Hgb as a covariate. For panel B, data are adjusted LSM (SE) change from BL derived from an MMRM analysis with terms for treatment (ferric citrate vs. PBO), BL albumin, BL log iFGF23, BL TSAT, BL ferritin, week, treatment 3 week interaction, treatment 3 ferritin interaction, and treatment 3 week 3 ferritin interaction as fixed effects, and BL Hgb as a covariate. Given the skewed distribution of iFGF23, this variable was log-transformed before analysis. **P < .01; ***P 5 .001. CI, confidence interval; FC, ferric citrate; FER, ferritin; iFGF23, intact fibroblast growth factor 23; LSM, least-squares mean; MMRM, mixed model for repeated measures; PBO, placebo; SE, standard error; TSAT, transferrin saturation
